Non Small Cell Lung Cancer Clinical Trial
— Acclaim-2Official title:
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Pembrolizumab Versus Docetaxel With or Without Ramucirumab in Patients With Previously Treated Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa), in combination with pembrolizumab in patients with previously treated NSCLC. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene, and is a systemic gene therapy. The study will be conducted in 2 phases, a dose escalation phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2). In Phase 1, patients will be enrolled in sequential cohorts treated with successively higher doses of quaratusugene ozeplasmid in combination with pembrolizumab to determine the recommended Phase 2 dose (RP2D). Phase 2 will be comprised of a dose expansion portion and a randomized portion. In the dose expansion portion, patients will be enrolled and treated with quaratusugene ozeplasmid at the RP2D in combination with pembrolizumab. In the randomized portion, patients will be randomized to receive either the investigational treatment of quaratusugene ozeplasmid at the RP2D in combination with pembrolizumab or a control treatment of either docetaxel +/- ramucirumab or the investigator's treatment of choice.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | November 2028 |
Est. primary completion date | November 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Patients will have their most recent archival tumor biopsy submitted to a central laboratory for IHC analysis. Inclusion Criteria: 1. Age =18 years. 2. Voluntarily signed an informed consent in accordance with institutional policies. 3. Histologically or cytologically documented NSCLC (SQ, NSQ, or mixed (adenosquamous) histology) with locally advanced or metastatic disease. Note: Any level of PD-L1 TPS is allowed. 4. Achieved clinical benefit to prior pembrolizumab or pembrolizumab/platinum-based chemotherapy for at least 3 months and subsequently progressed as confirmed by radiological tumor assessment per RECIST 1.1. Patients receiving pembrolizumab as a single agent must have additional therapy with a platinum-based chemotherapy prior to enrolling, but patients receiving pembrolizumab in combination with a platinum-based chemotherapy should have enrollment in this trial as the next treatment regimen. Chemotherapy is to be limited such that study treatment will be 2nd or 3rd line. 5. For Phase 2, patients must have measurable disease per RECIST 1.1. 6. Patients with genetic alterations with FDA-approved therapy (such as EGFR or anaplastic lymphoma kinase [ALK] mutations) must have disease progression after treatment with appropriate targeted therapy and must be eligible for immunotherapy as determined by the investigator. 7. ECOG performance status score from 0 to 1. 8. Must be =28 days beyond major surgical procedures such as thoracotomy, laparotomy, or joint replacement, and must be =10 days beyond minor surgical procedures such as biopsy of subcutaneous tumors, pleuroscopy, etc., and must not have evidence of wound dehiscence, active wound infection, or comparable major residual complications of the surgery. Note: Placement of pleural catheter despite being a minor surgical procedure, may be performed <10 days prior to study enrollment. 9. Demonstrate adequate organ function, as determined by the following laboratory values obtained within 21 days prior to enrollment: 1. Absolute neutrophil count (ANC) =1,500/µL, 2. Platelets = 100,000/µL, 3. Hemoglobin =8.0 g/dL =2 weeks without transfusions, 4. International normalized ratio (INR) or prothrombin time (PT): =1.5 × upper limit of normal (ULN) unless the patient is receiving anticoagulant therapy as long as PT is within therapeutic range of intended use of anticoagulants, 5. Activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT): =1.5 × ULN unless the patient is receiving anticoagulant therapy as long as aPTT is within therapeutic range of intended use of anticoagulants, 6. Creatinine =1.5 × ULN OR calculated creatinine clearance (CrCl) =60 mL/min for patients with creatinine levels >1.5 × ULN, 7. Serum total bilirubin =1.0 × ULN, 8. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =1.5 × ULN, 9. Alkaline phosphatase =2.5 x ULN. 10. Stable cardiac condition with a left ventricular ejection fraction >40% within =21 days prior to enrollment. 11. Asymptomatic brain metastases, must meet ALL of the following criteria (a-d): 1. No history of seizures in the preceding 6 months, 2. Definitive treatment must be completed =4 weeks prior to enrollment, 3. Stopped corticosteroid treatments administered because of brain metastases or related symptoms for =2 weeks prior to enrollment, 4. Post-treatment imaging must demonstrate stability or regression of the brain metastases. 12. Female patients of childbearing potential (FOCBP) must have a negative serum pregnancy test at screening (within 7 days of enrollment). Note: Non-childbearing potential is defined as greater than 1 year postmenopausal or surgically sterilized. 13. FOCBP and non-sterile male patients with female partner(s) of childbearing potential must agree to use 2 forms of contraception including 1 highly effective and 1 effective method beginning =2 weeks prior to enrollment through 4 months following the last dose of study treatment. 14. Male patients must agree to no sperm donation during study treatment and for an additional 4 months following the last dose of study treatment. Exclusion Criteria: 1. Unable to tolerate pembrolizumab treatment, leading to early treatment discontinuation or prolonged/frequent dosage modifications as determined by the investigator. 2. Hypersensitivity to docetaxel or polysorbate 80 (Phase 2 only). 3. Patients at risk of tumor lysis syndrome (e.g., renal impairment, hyperuricemia, bulky tumor [Phase 2 randomized portion only]). 4. Received prior systemic chemotherapy or monoclonal antibodies for the treatment of the participant's advanced or metastatic disease within 21 days of study enrollment. 5. Received prior gene therapy. 6. Received any radiotherapy to the skull, spine, thorax, or pelvis within 1 month of study enrollment. Note: Patients are permitted to have received palliative radiotherapy to an extremity provided at least 14 days has elapsed since completion of therapy, provided the patient received no more than 10 radiotherapy fractions and a dose no higher than 30 Gy to that site. 7. Expected to require any other form of antineoplastic therapy while participating in the study. 8. Received a live-virus vaccination within 1 month of enrollment. Seasonal flu vaccines that do not contain live virus are permitted. 9. Has known active, symptomatic CNS metastases and/or carcinomatous meningitis. 10. Active, known, or suspected autoimmune disease. 11. Active systemic viral, bacterial, or fungal infections(s) requiring treatment. 12. Serious concurrent illness or psychological, familial, sociological, geographical, or other condition that, in the opinion of the investigator, would prevent adequate follow-up and compliance with the study protocol. 13. A condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study enrollment. Inhaled or topical steroids and adrenal replacement doses =10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. 14. Active concurrent malignancies, i.e., cancers other than NSCLC. 15. Has a second, concurrent, untreated malignancy. 16. History of symptomatic interstitial lung disease or pneumonitis that required oral (PO) or IV glucocorticoids to assist with management. Note: Lymphangitic spread of the NSCLC is not an exclusion criterion. 17. History of myocardial infarction or unstable angina within 6 months prior to enrollment. 18. Presence of pre-existing peripheral neuropathy that is =Grade 2 by NCI-CTCAE v5.0 criteria. 19. Is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or has a recent history (within the last year) of substance abuse (including alcohol) requiring medical intervention. 20. Known human immunodeficiency virus (HIV) infection or has active hepatitis infection. 21. Female patients who are pregnant or breastfeeding. |
Country | Name | City | State |
---|---|---|---|
United States | Millennium Oncology | Houston | Texas |
United States | Washington University School of Medicine - Siteman Cancer Center | Saint Louis | Missouri |
United States | Moffitt Cancer Center - Magnolia Campus | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Genprex, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recommended Phase 2 Dose (RP2D) - Phase 1 | RP2D which will be the MTD or if the MTD is not defined by the safety data, the RP2D will be determined based on an integrated assessment of all available clinical safety, PK, and preliminary efficacy data. | First 21-days at each dose level | |
Primary | Progression-free Survival (PFS) - Phase 2 Dose Expansion | PFS rate at 18 weeks after first dose of study treatment. PFS according to RECIST. | 18 weeks | |
Primary | Progression-free Survival (PFS) - Phase 2 Randomized | PFS from randomization to disease progression or death. PFS according to RECIST. | Approximately 8 months | |
Secondary | Progression-free Survival (PFS) - Phase 1 | PFS from first study treatment to disease progression or death. PFS according to RECIST. | Approximately 8 months | |
Secondary | Overall Survival (OS) - Phase 1 | OS from first study treatment to death or discontinuation due to withdrawal of consent. | Approximately 11 months | |
Secondary | Pharmacokinetics (PK) - Phase 1 | Concentrations of quaratusugene ozeplasmid in whole blood samples. | First 21-day treatment cycle | |
Secondary | Adverse Events (AEs) - Phase 2 Dose Expansion | Number of treatment-related AEs graded according to the NCI-CTCAE. | Approximately 9 months] | |
Secondary | Progression-free Survival (PFS) - Phase 2 Dose Expansion | PFS from first study treatment to disease progression or death. PFS according to RECIST. | Approximately 8 months | |
Secondary | Overall Response Rate (ORR) - Phase 2 Dose Expansion | ORR (Complete Response [CR] + Partial Response [PR]) using best overall response from first study treatment to disease progression or death per RECIST compared to baseline tumor measurements. | Approximately 8 months | |
Secondary | Overall Survival (OS) - Phase 2 Dose Expansion | OS from first study treatment to death or discontinuation due to withdrawal of consent. | Approximately 11 months | |
Secondary | Pharmacokinetics (PK) - Phase 2 Dose Expansion | Concentrations of quaratusugene ozeplasmid in whole blood samples. | First 21-day treatment cycle | |
Secondary | Overall Response Rate (ORR) - Phase 2 Randomized | ORR (CR + PR) using best overall response from randomization to disease progression or death per RECIST compared to baseline tumor measurements. | Approximately 8 months | |
Secondary | Overall Survival (OS) - Phase 2 Randomized | OS from randomization to death or discontinuation due to withdrawal of consent. | Approximately 11 months | |
Secondary | Disease Control Rate (DCR) - Phase 2 Randomized | DCR (CR + PR + Stable Disease [SD]) using best overall response from randomization to death or discontinuation due to withdrawal of consent per RECIST compared to baseline tumor measurements. | Approximately 8 months | |
Secondary | Adverse Events (AEs) - Phase 2 Randomized | Number of treatment-related AEs graded according to the NCI-CTCAE. | Approximately 9 months | |
Secondary | Pharmacokinetics (PK) - Phase 2 Randomized | Concentrations of quaratusugene ozeplasmid in whole blood samples. | First 21-day treatment cycle |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Completed |
NCT03780010 -
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
|
Phase 1 |